Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mechel reported for 6 months of 2023 by RAS

8/16/23 MTLR

Rosbank reported for 6 months of 2023 by IFRS

8/16/23 ROSB

JD.com reported for 6 months of 2023

8/16/23 JD

Gazprom Neft will launch an oil refining complex at the Omsk Refinery

8/16/23 SIBN

Derivatives market participants demonstrated record activity

8/16/23 MOEX

Ural Kuznitsa reported for 6 months of 2023 by RAS

8/16/23 URKZ

Korshunovsky GOK reported for 6 months of 2023 by RAS

8/16/23 KOGK

Headhunter reported for 6 months of 2023

8/16/23 HEAD

Yandex will increase the number of robot couriers by more than 60%

8/16/23 YNDX

RusHydro is focused on the growth of absolute dividends

8/16/23 HYDR